Seven-Year Outcomes After Hysteroscopic and Laparoscopic Sterilizations.
Journal
Obstetrics and gynecology
ISSN: 1873-233X
Titre abrégé: Obstet Gynecol
Pays: United States
ID NLM: 0401101
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
pubmed:
12
1
2019
medline:
16
11
2019
entrez:
12
1
2019
Statut:
ppublish
Résumé
To evaluate 7-year outcomes after hysteroscopic and laparoscopic sterilizations, including subsequent tubal interventions and hysterectomies. This observational cohort study included women undergoing hysteroscopic and laparoscopic sterilizations in outpatient and ambulatory surgical settings in New York State during 2005-2016. We examined subsequent procedures (tubal ligation or resection, and hysterectomy not related to uterine leiomyomas or gynecologic tumors) after the index procedures. After propensity score matching, we used Kaplan-Meier analysis to obtain estimated risks of subsequent procedures within 7 years of index sterilization procedures, and Cox proportional hazard models to compare the differences between groups. We identified 10,143 and 53,206 women who underwent interval hysteroscopic and laparoscopic sterilizations, respectively, in New York State during 2005-2016. The mean age of the cohort was 34.2 years (range 18-80). The propensity score-matched cohort consisted of 10,109 pairs of women. The estimated risk of undergoing an additional tubal ligation or resection within 7 years was higher after hysteroscopic sterilization than it was after laparoscopic sterilization (3.9% vs 1.6%, HR 2.89, 95% CI 2.33-3.57). The difference was most pronounced within the initial year after attempted sterilization (1.5% vs 0.2%; HR 6.39, 95% CI 4.16-9.80). There was no significant difference in the risk of receiving a hysterectomy (0.9% vs 1.2%; HR 0.73, 95% CI 0.53-1.00) between women who underwent hysteroscopic and laparoscopic sterilizations. Patients undergoing hysteroscopic sterilization have a higher risk of receiving an additional tubal resection or ligation than those undergoing laparoscopic sterilization, particularly within the first year of the index procedure. There is no difference in undergoing a subsequent hysterectomy between the two groups. With limited evidence of outcomes after hysteroscopic sterilization beyond 7 years and existing reports of removals years after initial implantations, continuous monitoring of long-term outcomes for women who received the device is warranted.
Identifiants
pubmed: 30633141
doi: 10.1097/AOG.0000000000003092
pii: 00006250-201902000-00013
doi:
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
323-331Subventions
Organisme : FDA HHS
ID : U01 FD005478
Pays : United States
Références
Kerin JF, Cooper JM, Price T, Herendael BJ, Cayuela-Font E, Cher D, et al. Hysteroscopic sterilization using a micro-insert device: results of a multicentre phase II study. Hum Reprod 2003;18:1223–30.
Chudnoff SG, Nichols JE Jr, Levie M. Hysteroscopic essure inserts for permanent contraception: extended follow-up results of a phase III multicenter international study. J Minim Invasive Gynecol 2015;22:951–60.
Dennis B. FDA to review safety of controversial women's sterilization device. Available at: https://www.washingtonpost.com/national/health-science/fda-to-review-safety-of-controversial-womens-sterilization-device/2015/09/21/472aecb2-5b20-11e5-8e9e-dce8a2a2a679_story.html?utm_term=.91854cca204b. Retrieved March 7, 2018.
Whitman E. Thousands of women sue Bayer over medical issues using Bayer's Essure. Available at: http://www.modernhealthcare.com/article/20170429/MAGAZINE/170429836. Retrieved March 7, 2018.
U.S. Food and Drug Administration. FDA activities: Essure. Available at: https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/EssurePermanentBirthControl/ucm452254.htm. Retrieved March 7, 2018.
U.S. Food and Drug Administration. Labeling for permanent hysteroscopically-placed tubal implants intended for sterilization: guidance for industry and Food and Drug Administration staff. Available at: https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM488020.pdf. Retrieved March 7, 2018.
Mao J, Pfeifer S, Schlegel P, Sedrakyan A. Safety and efficacy of hysteroscopic sterilization compared with laparoscopic sterilization: an observational cohort study. BMJ 2015;351:h5162.
Antoun L, Smith P, Gupta JK, Clark TJ. The feasibility, safety, and effectiveness of hysteroscopic sterilization compared with laparoscopic sterilization. Am J Obstet Gynecol 2017;217:570 e1–6.
Bouillon K, Bertrand M, Bader G, Lucot JP, Dray-Spira R, Zureik M. Association of hysteroscopic vs laparoscopic sterilization with procedural, gynecological, and medical outcomes. JAMA 2018;319:375–87.
Perkins RB, Morgan JR, Awosogba TP, Ramanadhan S, Paasche-Orlow MK. Gynecologic outcomes after hysteroscopic and laparoscopic sterilization procedures. Obstet Gynecol 2016;128:843–52.
Block J. This birth control device kept making women sick. The FDA kept it on the market. Available at: https://www.huffingtonpost.com/entry/opinion-block-essure-contraception-fda_us_5abe8ec0e4b0f112dc9c2e69. Retrieved July 9, 2018.
Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care 1998;36:8–27.
American Cancer Society. Cancer facts & figures 2017. Available at: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2017/cancer-facts-and-figures-2017.pdf. Retrieved April 19, 2018.
Rassen JA, Shelat AA, Myers J, Glynn RJ, Rothman KJ, Schneeweiss S. One-to-many propensity score matching in cohort studies. Pharmacoepidemiol Drug Saf 2012;21(suppl 2):69–80.
U.S. Food and Drug Administration. 522 postmarket surveillance studies. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pss.cfm?t_id=356&c_id=3854. Retrieved March 7, 2018.
U.S. Food and Drug Administration. Statement from FDA Commissioner Scott Gottlieb, M.D., on manufacturer announcement to halt Essure sales in the U.S.; agency's continued commitment to postmarket review of Essure and keeping women informed. Available at: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm614123.htm. Retrieved July 23, 2018.
Maassen LW, van Gastel DM, Haveman I, Bongers MY, Veersema S. Removal of Essure sterilization devices: a retrospective cohort study in the Netherlands. J Minim Invasive Gynecol 2018 Oct 16 [Epub ahead of print].
Essure—permenant birth control. Available at: http://www.essure.com/. Retrieved July 23, 2018.
U.S. Food and Drug Administration. Statement from FDA Commissioner Scott Gottlieb, M.D., on new steps to strengthen the long-term safety oversight of the Essure device following discontinuation of its U.S. sales. Available at: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm628957.htm. Retrieved December 20, 2018.